DDW 2026: key readouts from the conference
DDW 2026: key readouts from the conference
Publish Date: 2026-05-06 07:54:00
Source Domain: www.pharmaceutical-technology.com
Pharmaceutical Technology rounds up the key readouts from Digestive Disease Week 2026. Credit: Kaczmarek-W / Shutterstock.com.
At the 2026 Digestive Disease Week (DDW) conference, there was significant buzz around certain pharma and medical device readouts, with key results spanning across oesophageal disorders, inflammatory bowel diseases (IBD) and digestive oncology.
As the meeting, which took place between 2-5 May in Chicago, draws to a close, Pharmaceutical Technology examines the key readouts from the conference and the future impact they may have on the market.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Find out more
AbbVie’s Skyrizi shows real-world benefit
One of the key focal points at DDW 2026 was IBD, with several companies presenting results from key drug trials across Crohn’s disease and ulcerative colitis (UC).
This includes prominent immunology player AbbVie, which touted long-term follow-up data from its real-world ASPIRE-CD study (NCT03105102) on blockbuster IL-23 blocker, Skryizi (risankizumab) in Crohn’s disease. This trial found that use of corticosteroids amongst patients dropped from 34% at baseline to 7% by week 52, while 25% and 46% of those who had Crohn’s-linked arthritis and skin conditions experienced relief from these symptoms at the end of the study period.
Skyrizi was also found to improve health-related quality of life (QoL), with 77% of…
